During the first week of treatment , the recommended starting dose of semaglutide GLP-1 is typically 0.25 mg once a week
The overall pattern was similar across age, sex, body size, blood sugar level, and the most commonly used medications within this drug class
The efficacy and safety of the new GLP-1 medicines continues to garner interest and will be discussed #ADA2024 Here is an updated safety-focused summary of the field and where it might be headed @DiabetesCareADA #T2D #obesity pic.twitter.com/rtEQYtHQG0 Daniel J Drucker (@DanielJDrucker) June 6, 2024 Investigational GLP-1 medicines in the clinic Late-stage investigational GLP-1 medicines for type 2 diabetes and obesity include new molecules like retatrutide and orforglipron, showing potential differentiation from semaglutide and tirzepatide through better tolerability, greater weight loss, Hb A 1c reduction, and targeted outcomes
Read the full breakdown: #Peptides #BPC157 #TB500 #FDA #HealthcareLaw #MedSpa #LengeaLaw #CompoundingPharmacy #MedicalCompliance To view or add a comment, sign in Tomorrow, the FDA makes one of its biggest moves yet on peptides
